<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234127</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0244</org_study_id>
    <nct_id>NCT03234127</nct_id>
  </id_info>
  <brief_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</brief_title>
  <acronym>SAFIR</acronym>
  <official_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of SAFIR is to identify the atherosclerotic genetic factors in these&#xD;
      patients, which will identify new therapeutic targets for the treatment of CV and Familial&#xD;
      Hypercholesterolemia diseases. In addition, SAFIR will allow the identification of new CV&#xD;
      protection biomarkers, which will be useful tools for the development of a personalized&#xD;
      medicine for the management of dyslipidemias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the SAFIR study is to perform non-invasive coronary vascular phenotyping of&#xD;
      familial hypercholesterolemia (FH) families by performing a coronary calcium score and then&#xD;
      to detect protective genetic factors in patients who do not have a significant atheroma&#xD;
      despite a perturbed biological phenotype.&#xD;
&#xD;
      The investigators will also conduct biochemical, lipidemic and metabolomic analyzes to&#xD;
      identify a signature of biomarkers protective of cardiovascular risk in FH patients.&#xD;
&#xD;
      The investigators will use the French FH register, which already includes 3889 patients, to&#xD;
      identify these &quot;protected&quot; FH families within the main reference centers for the management&#xD;
      of FH for inclusion and follow-up of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">May 6, 2021</completion_date>
  <primary_completion_date type="Actual">May 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genes associated with the resistance to development of coronary atherosclerosis in subjects with heterozygous familial hypercholesterolemia</measure>
    <time_frame>3 years</time_frame>
    <description>Identification of functional genetic variants by a Whole Genome Sequencing (WGS) approach in case-control analysis (FH without and with advanced coronary atherosclerosis) and/or family analysis (protected and affected relatives)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of new biochemical, lipidemic, metabolomic and metagenomic biomarkers associated with cardiovascular protection in FH patients.</measure>
    <time_frame>3 years</time_frame>
    <description>Lipidic panel, phosphocalcic panel, Ceramides, Alipoproteins, Lp(a), lipidomic, LDL size, Phospholipids, TMAO, Carnitin, Cholin, microbiota, metabolomic, LDL Ox, Sterols, Isoprostan, oxidation, inflammation, cytokins, oxidative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of arterial stiffness (reflected by the pulse wave velocity) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of arterial stiffness measured by popmeter® (pulse wave velocity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of supra-aortic trunks (AST) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of ASD through arterial Doppler ultrasonography (Intra-media thickness (IMT), degree of stenosis (ESCT), plaque)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of the lower limbs with the development of coronary atherosclerosis (PAD) in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of lower extremity involvement by arterial doppler ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between aortic valvular score and development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between coronary calcium score and aortic valvular score in HF patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">562</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH Patient without atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH patient with atheroclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the related population without familial hypercholesterolemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No FH patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole Genome Sequencing</intervention_name>
    <description>Whole Genome Sequencing Biomarkers analyses</description>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>the related population without familial hypercholesterolemia</arm_group_label>
    <other_name>Biological analyzes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient agreeing to sign the consent of the study and the consent of biocollection&#xD;
&#xD;
          -  Patient suffering from a familial hypercholesterolemia with a clinically-biologic&#xD;
             score DLCN (Dutch Lipid Clinic Network, Annex 2)&gt; 8 and / or a causative mutation&#xD;
             identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.&#xD;
&#xD;
          -  Men ≥ 40 years of age; Female ≥ 50 years&#xD;
&#xD;
          -  Patient affiliated to an existing social insurance&#xD;
&#xD;
        The inclusion criteria to be met in the population with known coronary atheroma:&#xD;
&#xD;
          -  Subject in secondary prevention of an atheromatous disease: coronary event or ischemic&#xD;
             heart disease, irrespective of the result of the coronary calcium score; Ischemic&#xD;
             stroke with proven carotid atheromatosis; revascularization (angioplasty, bypass&#xD;
             surgery) or amputation in PAD&#xD;
&#xD;
          -  Primary prevention topic CV with calcium score ≥ 400 Agatston units&#xD;
&#xD;
        Inclusion criteria to be met in the population without cardiovascular risk:&#xD;
&#xD;
        - No cardiovascular event (including MI, coronary revascularization, angina, stroke &amp;,&#xD;
        Transiant ischemic attack of atheromatous origin, PAD) with: For women between 50 and 65&#xD;
        years, a nil calcium score * For women between 65 and 75 years of age, a calcium score** ≤&#xD;
        10 Agatston units For women over 75 years of age, a calcium score** ≤ 20 Agatston units For&#xD;
        men between 40 and 55 years of age, a nil calcium score* for men For men between 55 and 70&#xD;
        years of age, a calcium score** ≤ 10 Agatston units For men over 70 years of age, a calcium&#xD;
        score** ≤ 20 Agatston units&#xD;
&#xD;
          -  40 year old men and 50 year old women: less than 6 months old&#xD;
&#xD;
          -  41 year old men and 51 year old women: under 1 year old&#xD;
&#xD;
          -  42 year old men and 52 year old women: under 2 years old&#xD;
&#xD;
          -  43 year old men and 53 year old women: under 3 years old&#xD;
&#xD;
          -  44 year old men and 54 year old women: under 4 years old&#xD;
&#xD;
               -  Less than 5 years&#xD;
&#xD;
        Inclusion criteria to be met in the related population with familial hypercholesterolemia :&#xD;
&#xD;
          -  Patient agreeing to sign the consent of the study and the consent of biocollection&#xD;
&#xD;
          -  Patient suffering from a familial hypercholesterolemia with a clinically-biologic&#xD;
             score DLCN (Dutch Lipid Clinic Network, Annex 2)&gt; 8 and / or a causative mutation&#xD;
             identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.&#xD;
&#xD;
          -  Men or Female ≥ 30 years&#xD;
&#xD;
          -  Patient affiliated to an existing social insurance&#xD;
&#xD;
        Inclusion criteria to be met in the related population without familial&#xD;
        hypercholesterolemia :&#xD;
&#xD;
          -  Patient agreeing to sign the consent of the study and the consent of biocollection&#xD;
&#xD;
          -  Patient not suffering from a familial hypercholesterolemia related to one of the&#xD;
             members of the population suffering from familial hypercholesterolemia without&#xD;
             cardiovascular risk&#xD;
&#xD;
          -  Men or Female ≥ 18 years&#xD;
&#xD;
          -  Patient affiliated to an existing social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject suffering from active cancer or progressive neoplasia&#xD;
&#xD;
          -  Subject treated with recent corticosteroid therapy&#xD;
&#xD;
          -  Subjects with unsubstituted or poorly controlled hypothyroidism (TSH&gt; normal)&#xD;
&#xD;
          -  Subject receiving immunosuppressive or anti-cancer treatment&#xD;
&#xD;
          -  Subject refusing to participate&#xD;
&#xD;
          -  Subjects under tutelage, curatorship or a safeguard of justice or without social&#xD;
             insurance&#xD;
&#xD;
        The exclusion criterion for all populations except the related population without familial&#xD;
        hypercholesterolemia:&#xD;
&#xD;
        - Subject with no &quot;definite&quot; familial hypercholesterolemia according to the DLCN score&#xD;
        (≤8), after auction. The purpose of the auction will be to rule on the causal nature of an&#xD;
        identified mutation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Le Bocage Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>29079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Pradel Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Conception Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

